ストックスクリーナーアプリを入手
3.04
1.33%
0.04
プレマーケット:
3.10
0.06
+1.97%
前日終値:
$3.00
開ける：
$3.06
24時間の取引高:
1.33M
Relative Volume:
1.62
時価総額：
$100.53M
収益：
$1.23M
当期純損益:
$-28.62M
株価収益率:
-1.9366
EPS:
-1.5698
ネットキャッシュフロー:
$-14.11M
1週間 パフォーマンス:
+3.05%
1か月 パフォーマンス:
+38.18%
6か月 パフォーマンス:
+14.29%
1年 パフォーマンス:
+49.75%
1日の値動き範囲:
$3.0282
$3.21
1週間の範囲:
$2.85
$3.21
52週間の値動き範囲:
$1.62
$3.84
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Compare NRXP vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
3.04 | 99.20M | 1.23M | -28.62M | -14.11M | -1.5698 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-08 | 開始されました | H.C. Wainwright | Buy |
| 2025-04-02 | 開始されました | BTIG Research | Buy |
Nrx Pharmaceuticals Inc (NRXP) 最新ニュース
NRx Pharmaceuticals, Inc. (NRXP) Latest Stock News & Headlines - Yahoo Finance
Amid ketamine shortages, NRx begins making a preservative-free U.S. version - Stock Titan
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of - GlobeNewswire
NRXP Stock Price, Quote & Chart | NRX PHARMACEUTICALS INC (NASDAQ:NRXP) - ChartMill
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Sees Large Growth in Short Interest - MarketBeat
NRx Pharmaceuticals, Inc. (NRXP) surpasses Q4 earnings estimates - MSN
NRx Reports FDA Feedback, Progress on Ketamine Application - MyChesCo
Equities Analysts Offer Predictions for NRXP Q1 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), NRX Pharmaceuticals (NRXP) and Immuneering (IMRX) - The Globe and Mail
NRXP Forecast, Price Target & Analyst Ratings | NRX PHARMACEUTICALS INC (NASDAQ:NRXP) - ChartMill
NRx Pharmaceuticals (NASDAQ:NRXP) Earns "Buy" Rating from HC Wainwright - MarketBeat
NRx Pharmaceuticals (NASDAQ:NRXP) Price Target Raised to $49.00 at Ascendiant Capital Markets - MarketBeat
H.C. Wainwright reiterates NRx Pharmaceuticals stock rating on FDA progress - Investing.com
H.C. Wainwright reiterates NRx Pharmaceuticals stock rating on FDA progress By Investing.com - Investing.com India
NRx Pharmaceuticals gets FDA approval for suitability petition of Ketafree - MSN
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global - Scott Coop
Positive FDA Response on Preservative-Free Ketamine After President Trump Orders Accelerated Approval for Psychedelic Medication Developers Including NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart.com
NRx Pharmaceuticals (NASDAQ: NRXP) Receives Positive FDA Review Letter Supporting Ketamine ANDA Progress - Barchart.com
NRx Pharmaceuticals receives FDA positive review for ketamine ANDA By Investing.com - Investing.com India
NRXP (NRX Pharmaceuticals Inc.) posts wider than expected Q4 2025 loss even as shares rise modestly today.Earnings Season - Cổng thông tin điện tử tỉnh Tây Ninh
NRX Pharmaceuticals (NRXP) Sector Rotation | Q4 2025: Earnings Fall ShortProfessional Trade Ideas - Xã Thanh Hà
NRX Pharmaceuticals, Inc. Common Stock (NRXP) Stock Price Today & Analysis - Gotrade
Positive FDA Response on Preservative-Free Ketamine After - openPR.com
NRx Pharmaceuticals receives FDA positive review for ketamine ANDA - Investing.com
NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program - The Manila Times
NRXP Financials: Income Statement, Balance Sheet & Cash Flow | Nrx Pharmaceuticals Inc - Stock Titan
FinancialContentPresidential Executive Order to Accelerate Approval of Psychedelic Medications; Those Being Developed by NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - FinancialContent
NRXP Ownership | NRX PHARMACEUTICALS INC (NASDAQ:NRXP) - ChartMill
NRx Pharmaceuticals Appoints Glenn Tyson as Chief Commercial Officer - MyChesCo
NRx Pharmaceuticals, Inc. (NRXPW) Stock Price, News, Quote & History - Yahoo Finance
NRx Re-Files FDA Application for Preservative-Free IV Ketamine - MSN
NRx Pharmaceuticals Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality - Investing News Network
NRx Pharmaceuticals (NASDAQ: NRXP) Supports Executive Order To Accelerate Psychedelic Drug Development - The Globe and Mail
NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital - Moomoo
NRx Pharmaceuticals welcomes the newly-signed Executive Order - TipRanks
NRx Pharmaceuticals' (NRXP) Buy Rating Reiterated at D. Boral Capital - MarketBeat
NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality - ChartMill
NRx says FDA finds no bioequivalence issues in ketamine filing - MSN
NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications - Investing News Network
User - The Chronicle-Journal
NRx Pharmaceuticals forms defense R&D subsidiary By Investing.com - Investing.com Australia
AI-Driven Neurotechnology Expansion as FDA Path Clears and New Defense Initiative Emerges for NRx Pharmaceuticals (N A S D A Q: NRXP) - WFMZ.com
NRx Pharmaceuticals (NASDAQ: NRXP) Forms NRx Defense Systems Subsidiary to Advance Neuroplastic Therapies for Military and Government Applications - Barchart
NRx Pharmaceuticals Advances Robotic TMS and Neuroplastic Therapy for Military and First Responders - citybiz
NRx Pharmaceuticals Forms Defense Subsidiary to Develop AI-Enabled Neuroplastic Therapies - citybiz
Nrx Pharmaceuticals Inc (NRXP) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):